To amend the Federal Food, Drug, and Cosmetic Act to require labeling containing information applicable to pediatric patients.
Latest action · Oct 28, 2002 Referred to the Subcommittee on Health.
Progress
Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.
- IntroducedOct 9, 2002
- Passed HouseNot reached
- Passed SenateNot reached
- To the PresidentNot reached
- Became lawNot reached
Summary
Permits extrapolation from adult studies where the course of the disease and the effects of the drug are sufficiently similar in all populations.
Permits deferral of such assessments if adult studies are completed earlier and the applicant submits a plan for or a description of planned or ongoing pediatric studies.
Permits full waiver of such assessments if: (1) studies are highly impractical or impossible; (2) the evidence strongly suggests that the drug or product would be ineffective or unsafe in all pediatric age groups; (3) there is no meaningful therapeutic advantage or benefit in the pediatric population; or (4) the drug or product is not likely to be used in a substantial number of pediatric patients.
Permits partial waivers at the request of an applicant for a specific pediatric subpopulation if any of the full waiver grounds apply to that subpopulation or reasonable attempts for a pediatric formulation for that subpopulation have failed.
Requires labels to provide indication in cases in which a waiver has been granted due to evidence a product would be unsafe or ineffective in pediatric populations.
Authorizes the Secretary of Health and Human Services to specify a date for submission of pediatric assessments if: (1) the drug or biological product would represent a meaningful therapeutic benefit for pediatric patients for one or more claimed indications and the absence of adequate labeling could pose significant risks to pediatric patients; or (2) it is used for a number of pediatric patients for the labeled indications and the absence of adequate labeling could pose significant risks to pediatric patients. Sets forth criteria for full waiver and partial waivers of such requirement. Requires labels to provide indication in cases in which a waiver has been granted due to evidence a product would be unsafe or ineffective in pediatric populations.
Requires the Secretary to issue a written request for related pediatric studies under the Public Health Service Act before requiring an assessment for a drug.
States that drugs or products with delayed assessments may be deemed misbranded and subject to seizure and injunctive proceedings, though not penalties.
Cosponsors 1
Members who signed on, in the order they did. All signed on Oct 9, 2002.
| Seat | Cosponsor | Signed on | |
|---|---|---|---|
| R-OH | Deborah Pryce | Original | Oct 9, 2002 |
Committees 1
Where it was sent and what each committee and subcommittee did with it, in order.
| Chamber | Committee | What it did |
|---|---|---|
| House | Energy and Commerce Committee | Referred Oct 9, 2002 |
| Health Subcommittee | Referred Oct 28, 2002 |
Actions 3
Everything that happened, newest first.
- Oct 28, 2002Referred to the Subcommittee on Health.
- Oct 9, 2002Introduced in House
- Oct 9, 2002Referred to the House Committee on Energy and Commerce.
Titles 1
Every title it has carried, official and short, at each stage.
- Official Title as Introduced
- To amend the Federal Food, Drug, and Cosmetic Act to require labeling containing information applicable to pediatric patients.
Subjects
Assigned by the Library of Congress. Policy area: Health.
- Administrative procedure
- Child health
- Clinical trials
- Commerce
- Department of Health and Human Services
- Drug adulteration
- Drug approvals
- Drug industry
- Drugs
- Families
- Government Operations and Politics
- Government paperwork
- Health
- Injunctions
- Labeling
- Law
- Licenses
- Pharmaceutical research
- Product safety
- Science, Technology, Communications
- Searches and seizures
Text 1
Each version as it was printed, newest first.
- Oct 9, 2002Introduced in House
Support LegiList
This page is free, carries no paywall, and is built and maintained by one person. If the record here is useful to you, a few dollars keeps it going.
Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov; cost estimates are the Congressional Budget Office's, and the hearings are the printed hearings GovInfo publishes, which can appear months after the hearing.